This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/893,321	06/27/2001	D. Wade Walke	LEX-0195-USA 2099	
24231	7590 09/03/2002			
	GENETICS INCORE	EXAMINER		
8800 TECHNOLOGY FOREST PLACE THE WOODLANDS, TX 77381-1160			LANDSMAN, ROBERT S	
		·	ART UNIT	PAPER NUMBER
			1647	
			DATE MAILED: 09/03/2002	7

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)
		09/893,321	WALKE ET AL.
	Office Action Summary	Examiner	Art Unit
		Robert Landsman	1647
Period fo	Th MAILING DATE of this communication apports.	pears on the cover sheet wi	th the correspondenc address
THE - Exte after - If the - If NO - Failu - Any r	ORTENED STATUTORY PERIOD FOR REPL'MAILING DATE OF THIS COMMUNICATION. nsions of time may be available under the provisions of 37 CFR 1.1 SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a reply operiod for reply is specified above, the maximum statutory period vere to reply within the set or extended period for reply will, by statute reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a re y within the statutory minimum of thirt will apply and will expire SIX (6) MON	eply be timely filed y (30) days will be considered timely. THS from the mailing date of this communication.
1)	Responsive to communication(s) filed on		
2a) □		— · is action is non-final.	
3) 🗆	Since this application is in condition for allowa		toro proposition as to the second in
,	closed in accordance with the practice under on of Claims	Ex parte Quayle, 1935 C.E	D. 11, 453 O.G. 213.
4) 🖾	Claim(s) 1-4 is/are pending in the application.		
	4a) Of the above claim(s) is/are withdrav	vn from consideration.	
	Claim(s) is/are allowed.		
6) 🗌	Claim(s) is/are rejected.		
7)	Claim(s) is/are objected to.		
	Claim(s) <u>1-4</u> are subject to restriction and/or ele	ection requirement	
	on Papers	on rodanomone.	
9)□ T	he specification is objected to by the Examiner	•	
10)∐ T	he drawing(s) filed on is/are: a)☐ accep	ted or b) objected to by th	e Examiner.
	Applicant may not request that any objection to the		
11) 🗌 T	he proposed drawing correction filed on		
	If approved, corrected drawings are required in rep		•
12)∐ T	he oath or declaration is objected to by the Exa	miner.	
Priority u	nder 35 U.S.C. §§ 119 and 120		
13) 🔲 📝	Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. §	119(a)-(d) or (f)
	All b) Some * c) None of:	,	(4) (4) (5)
	1. Certified copies of the priority documents	have been received.	
	2. Certified copies of the priority documents		plication No
	Copies of the certified copies of the priority		
* Se	application from the International Bure se the attached detailed Office action for a list o	eau (PCT Rule 17 2(a))	•
14)∐ Ac	knowledgment is made of a claim for domestic	priority under 35 U.S.C. §	119(e) (to a provisional application).
a)	☐ The translation of the foreign language proveknowledgment is made of a claim for domestic	isional application has bee	n received
Attachment(s			U
) Notice (of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) Ition Disclosure Statement(s) (PTO-1449) Paper No(s)	5) L Notice of Info	mmary (PTO-413) Paper No(s) Drmal Patent Application (PTO-152) CE to Comp) y with Segurny Rules
Patent and Trad O-326 (Rev.	emark Office 04-01) Office Actie	on Summary	Part of Paper No. 6

Application/Control Number: 09/893,321

Art Unit: 1647

DETAILED ACTION

1. Election/Restriction

- A. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1 in part, 2 and 3, drawn to an isolated nucleic acid molecule related to SEQ ID
 NO:1 and encoding SEQ ID NO:2, classified in class 536, subclass 23.5.
 - II. Claims 1 in part, and 4, drawn to an isolated nucleic acid molecule related to SEQ ID NO:3, or encoding SEQ ID NO:4, classified in class 536, subclass 23.5.
- B. The inventions are distinct, each from each other because of the following reasons:

Inventions I and II are independent and distinct, each from each other, because they are products which possess characteristic differences in structure and function and each has an independent utility that is distinct for each invention which cannot be exchanged.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and recognized divergent subject matter as defined by MPEP § 808.02, the Examiner has *prima facie* shown a serious burden of search (see MPEP § 803). Therefore, an initial requirement of restriction for examination purposes as indicated is proper.

C. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 CFR § 1.48(b) and by the fee required under 37 CFR § 1.17 (h).

Application/Control Number: 09/893,321

Art Unit: 1647

Advisory information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert Landsman whose telephone number is (703) 306-3407. The examiner can normally be reached on Monday - Friday from 8:00 AM to 5:00 PM (Eastern time) and alternate Fridays from 8:00 AM to 5:00 PM (Eastern time).

If attempts to reach the examiner by telephone are unsuccessful, the Examiner's supervisor, Gary Kunz, can be reached on (703) 308-4623.

Official papers filed by fax should be directed to (703) 308-4242. Fax draft or informal communications with the examiner should be directed to (703) 308-0294.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Robert Landsman, Ph.D. Patent Examiner Group 1600 July 30, 2002

Page 3



HTS AND TRADEMARKS COMMISSIONER F Washington, D.C. 20231

ATTORNEY DOCKET NO. FIRST NAMED APPLICANT SERIAL NUMBER FILING DATE Lex-0195-USA Wale et al 667101 09/893 321

EXAMINER LANDSMAN PAPER NUMBER ART UNIT

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/ r amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid

APPLICANT IS GIVEN ONE EXTENDIBLE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO Sequence Disclosures. COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will . result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be whose telephone number is (703) 30 directed to

Application No.: 09/89332 (NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

	 This application clearly falls to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
Į.	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
₹.	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other: Applicant should follow the format of the attached sample statement to request that the CRF fill in the parent application be used to create a CRF in this application.
	Applicant Must Provide:
	An <u>initial</u> or substitute computer readable form (CRF) copy of the "Sequence Listing".
	An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(d).
	For questions regarding compliance to these requirements, please contact:
	• • • • • • • • • • • • • • • • • • •
	TO OUT SUUMISSION Help call (703) 308-4343
	Contraction Software help call (703) 308 against the software software help call (703) 308 against
	PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE